Tela Bio Inc (TELA)

$2.69 +0.03 (1.13%)
Market Cap 104.77M
Revenue (ttm) 58.45M
Net Income (ttm) -46.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -79.83%
Debt to Equity Ratio -6.53
Volume 44,800
Avg Vol 188,566
Day's Range N/A - N/A
Shares Out 39.39M
Stochastic %K 9%
Beta 1.00
Analysts Strong Sell
Price Target $9.20

Latest News on TELA

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 13, 2024, 4:05 PM EST - 5 weeks ago

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TELA Bio to Participate in Piper Sandler's 36th Annual Healthcare Conference

Nov 19, 2024, 4:05 PM EST - 2 months ago

TELA Bio to Participate in Piper Sandler's 36th Annual Healthcare Conference

TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 1:49 PM EST - 2 months ago

TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript

TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 24, 2024, 4:05 PM EDT - 3 months ago

TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Oct 23, 2024, 8:07 AM EDT - 3 months ago

TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

TELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Oct 22, 2024, 4:05 PM EDT - 3 months ago

TELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

TELA Bio to Announce Third Quarter 2024 Financial Results

Oct 17, 2024, 4:05 PM EDT - 3 months ago

TELA Bio to Announce Third Quarter 2024 Financial Results

TELA Bio, Inc. (TELA) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 8:37 PM EDT - 5 months ago

TELA Bio, Inc. (TELA) Q2 2024 Earnings Call Transcript

TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance

Aug 12, 2024, 4:05 PM EDT - 5 months ago

TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance

TELA Bio to Announce Second Quarter 2024 Financial Results

Jul 22, 2024, 4:05 PM EDT - 6 months ago

TELA Bio to Announce Second Quarter 2024 Financial Results

TELA Bio Appoints Jeffrey Blizard to its Board of Directors

Jun 4, 2024, 4:05 PM EDT - 8 months ago

TELA Bio Appoints Jeffrey Blizard to its Board of Directors

TELA Bio Appoints Greg Firestone as Chief Commercial Officer

May 20, 2024, 4:03 PM EDT - 8 months ago

TELA Bio Appoints Greg Firestone as Chief Commercial Officer

TELA Bio, Inc. (TELA) Q1 2024 Earnings Call Transcript

May 11, 2024, 2:35 PM EDT - 8 months ago

TELA Bio, Inc. (TELA) Q1 2024 Earnings Call Transcript

TELA Bio Reports First Quarter 2024 Financial Results

May 9, 2024, 4:05 PM EDT - 9 months ago

TELA Bio Reports First Quarter 2024 Financial Results

TELA Bio to Announce First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 9 months ago

TELA Bio to Announce First Quarter 2024 Financial Results

TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures

Apr 15, 2024, 7:00 AM EDT - 9 months ago

TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures

TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

Apr 8, 2024, 7:00 AM EDT - 10 months ago

TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

TELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 7:38 PM EDT - 10 months ago

TELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript

TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results

Mar 21, 2024, 4:05 PM EDT - 10 months ago

TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results

TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery

Mar 21, 2024, 7:00 AM EDT - 10 months ago

TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery

TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX

Mar 20, 2024, 7:00 AM EDT - 10 months ago

TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX

TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results

Feb 29, 2024, 7:00 AM EST - 11 months ago

TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results

TELA Bio: Looks Like A Buy, But Some Pieces Missing To Make This A Strong Buy

Jan 16, 2024, 2:34 AM EST - 1 year ago

TELA Bio: Looks Like A Buy, But Some Pieces Missing To Make This A Strong Buy

TELA Bio to Take Part in Connecting the Dots

Dec 5, 2023, 7:00 AM EST - 1 year ago

TELA Bio to Take Part in Connecting the Dots

TELA Bio to Participate in Piper Sandler's 35th Annual Healthcare Conference

Nov 16, 2023, 7:00 AM EST - 1 year ago

TELA Bio to Participate in Piper Sandler's 35th Annual Healthcare Conference

TELA Bio, Inc. (TELA) Q3 2023 Earnings Call Transcript

Nov 12, 2023, 1:42 AM EST - 1 year ago

TELA Bio, Inc. (TELA) Q3 2023 Earnings Call Transcript

TELA Bio Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 4:05 PM EST - 1 year ago

TELA Bio Reports Third Quarter 2023 Financial Results

TELA Bio to Announce Third Quarter 2023 Financial Results

Oct 26, 2023, 7:00 AM EDT - 1 year ago

TELA Bio to Announce Third Quarter 2023 Financial Results

TELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase

Sep 18, 2023, 4:05 PM EDT - 1 year ago

TELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase

TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

Aug 16, 2023, 7:00 AM EDT - 1 year ago

TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

TELA Bio, Inc. (TELA) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 9:00 PM EDT - 1 year ago

TELA Bio, Inc. (TELA) Q2 2023 Earnings Call Transcript

TELA Bio Reports Second Quarter 2023 Financial Results

Aug 9, 2023, 4:03 PM EDT - 1 year ago

TELA Bio Reports Second Quarter 2023 Financial Results

TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference

Jul 26, 2023, 7:00 AM EDT - 1 year ago

TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference

New Survey Finds Strong Consumer Preference for More Natural Hernia Repair Options

Jun 15, 2023, 7:00 AM EDT - 1 year ago

New Survey Finds Strong Consumer Preference for More Natural Hernia Repair Options

TELA Bio to Participate in the Jefferies Global Healthcare Conference

May 25, 2023, 7:00 AM EDT - 1 year ago

TELA Bio to Participate in the Jefferies Global Healthcare Conference

TELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver Lab

May 19, 2023, 7:00 AM EDT - 1 year ago

TELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver Lab

TELA Bio, Inc. (TELA) Q1 2023 Earnings Call Transcript

May 14, 2023, 12:21 PM EDT - 1 year ago

TELA Bio, Inc. (TELA) Q1 2023 Earnings Call Transcript

TELA Bio Reports First Quarter 2023 Financial Results

May 11, 2023, 4:02 PM EDT - 1 year ago

TELA Bio Reports First Quarter 2023 Financial Results

TELA Bio Supports Diversity and Inclusion at International Hernia Collaboration Conference

May 9, 2023, 7:00 AM EDT - 1 year ago

TELA Bio Supports Diversity and Inclusion at International Hernia Collaboration Conference

TELA Bio to Participate in the JMP Securities Life Sciences Conference

May 2, 2023, 7:00 AM EDT - 1 year ago

TELA Bio to Participate in the JMP Securities Life Sciences Conference

TELA Bio to Announce First Quarter 2023 Financial Results

Apr 27, 2023, 7:00 AM EDT - 1 year ago

TELA Bio to Announce First Quarter 2023 Financial Results

Why TELA Bio Stock Is Dropping Today - TELA Bio (NASDAQ:TELA)

Apr 19, 2023, 2:27 PM EDT - 1 year ago

Why TELA Bio Stock Is Dropping Today - TELA Bio (NASDAQ:TELA)

TELA Bio Announces Pricing of Public Offering of Common Stock

Apr 18, 2023, 11:00 PM EDT - 1 year ago

TELA Bio Announces Pricing of Public Offering of Common Stock

TELA Bio Announces Proposed Public Offering of Common Stock

Apr 18, 2023, 4:01 PM EDT - 1 year ago

TELA Bio Announces Proposed Public Offering of Common Stock

TELA Bio's OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023

Mar 29, 2023, 7:00 AM EDT - 1 year ago

TELA Bio's OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023

TELA Bio Announces 510(k) Clearance for OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

Mar 23, 2023, 7:00 AM EDT - 1 year ago

TELA Bio Announces 510(k) Clearance for OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

TELA Bio, Inc. (TELA) Q4 2022 Earnings Call Transcript

Mar 21, 2023, 8:05 PM EDT - 1 year ago

TELA Bio, Inc. (TELA) Q4 2022 Earnings Call Transcript

TELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 21, 2023, 4:02 PM EDT - 1 year ago

TELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results

TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications

Mar 16, 2023, 7:00 AM EDT - 2 years ago

TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications

TELA Bio to Announce Fourth Quarter and Full Year 2022 Financial Results

Feb 28, 2023, 7:00 AM EST - 2 years ago

TELA Bio to Announce Fourth Quarter and Full Year 2022 Financial Results